Cetuximab therapy for head and neck squamous cell carcinoma: A systematic review of the data

Otolaryngology - Head and Neck Surgery

Volumn 144, Issue 5, 2011, Pages 676-684

  Reeves, Travis D ^a   Hill, Elizabeth G ^b   Armeson, Kent E ^b   Gillespie, M Boyd ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cetuximab; Chemotherapy; Head and neck cancer; Squamous cell carcinoma; Systematic review

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; PACLITAXEL; PLACEBO; PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANAPHYLAXIS; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; HEAD AND NECK CARCINOMA; HUMAN; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; TREATMENT RESPONSE; HEAD AND NECK TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS;

EID: 80051745944     PISSN: 01945998     EISSN: 10976817     Source Type: Journal    
DOI: 10.1177/0194599811399559     Document Type: Review

References (28)

1. Gold KA, Lee H-Y, Kim ES. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer. 2009;115: 922-935.
2. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358:1160-1174.
3. Gebbia V, Giuliani F, Valori VM, Agueli R, Colucci G, Maiello E. Cetuximab in squamous cell head and neck carcinomas. Ann Oncol. 2007;18:vi5-vi7.
4. Bourhis J. New approaches to enhance chemotherapy in SCCHN. Ann Oncol. 2005;16:vi20-vi24. (Pubitemid 41487947)
5. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350-7356. (Pubitemid 36025259)
6. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors. Cancer. 2002;94: 1593-1611. (Pubitemid 34212655)
7. Normand ST. Meta analysis: formulating, evaluating, combining, and reporting. Stat Med. 1999;18:321-359.
8. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Stat Med. 1998;17:2815-2834. (Pubitemid 28562978)
9. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/ or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25:2171-2177. (Pubitemid 46954639)
10. Burtness B, Goldwater MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23(34):8646-8654. (Pubitemid 46211507)
11. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austriaa; Foundation for Statistical Computing; 2009.
12. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21-28.
13. Shin DM, Donato NJ, Perez-Soler R, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res. 2001;7: 1204-1213. (Pubitemid 32708671)
14. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of antiepidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000; 18:904-914. (Pubitemid 30106623)
15. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116-1127.
16. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578. (Pubitemid 43209104)
17. Kies MS, Holsinger FC, Lee JJ, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol. 2010;28:8-14.
18. Gillison ML, D'Souza G, Westra W. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100:407-420. (Pubitemid 351480511)
19. Psyrri A, DiMaio D. Human papillomavirus in cervical and head and neck cancer. Nat Clin Pract Oncol. 2008;5:24-31. (Pubitemid 351512426)
20. Goldenberg D, Begum S, Westra WH. Cystic lymph node metastasis in patients with head and neck cacner: an HPV-associated phenomenon. Head Neck. 3008;30:898-903.
21. Haddad RI, Tishler RB, Norris C, et al. Phase I study of CTPF in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2009;27:4448-4453.
22. Bourhis J, Rivera F, Mesia R, et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;24:2866-2872. (Pubitemid 46630587)
23. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the natiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/ or recurrent squamous cell carcinoma of head and neck. J Clin Oncol. 2005;23:5568-5577.
24. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23:5578-5587.
25. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2001;19:3234-3243. (Pubitemid 32591441)
26. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study for a new combined-modality paradigm. J Clin Oncol. 2006;24:1072-1078. (Pubitemid 46638804)
27. Balermpas P, Hambek M, Seitz O, Rodel C, Weiss C. Combined cetuximab and re-irradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck. Strahlenther Onkol. 2009;185:775-781.
28. Birnbaum A, Dipretrillo T, Rathore R, et al. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer. Am J Clin Oncol. 2010;33:144-147.